VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Alpha-type-1 Polarized Dendritic Cells
Vaccine Information
  • Vaccine Name: Alpha-type-1 Polarized Dendritic Cells
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Product Name: αDC1
  • Vaccine Ontology ID: VO_0007239
  • Type: Other
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • Antigen: The αDC1vaccine can stimulate CTL response against melanoma antigens including MLANA, gp100 (PMEL), and Tyrosinase (Mailliard et al., 2004).
  • MLANA gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • gp100 (PMEL) gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Tyrosinase gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: Treating dendritic cells (DCs) is treated with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) (Mailliard et al., 2004)
  • Description: A mature polarized dendritic cell with potent immunostimulating activity. Treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma) produces mature but not exhausted alpha type-1 polarized DCs (alphaDC1) that are capable of: 1) high responsiveness to other lymphoid chemokines, and 2) producing high level of interleukin-12p70 (IL-12p70). Therefore, alphaDC1 has a much more significant capability of inducing helper T cell (CD4+ T-cell) responses in comparison with the "gold standard" DCs. When pulsed with specific tumor associated antigens (TAAs), alphaDC1 is able to induce a potent cytotoxic T lymphocyte (CTL) response against TAAs; as a result it can be used as a cancer vaccine. (NCIT_C64846).

    This vaccine has been used in trials involving melanoma, breast, ovarian and fallopian tube cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/alpha-type-1-polarized-dendritic-cells
Host Response
References
Mailliard et al., 2004: Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer research. 2004; 64(17); 5934-5937. [PubMed: 15342370].
NCIT_C64846: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64846]